The drug, flibanserin, known commercially as Addyi, was developed by a German drug firm and acquired by a small North Carolina drug company that in turn was bought by Canadian pharma giant Valeant for a billion dollars in cash a day after the FDA approved its use by women suffering from low libido. That FDA approval came in the wake of a studied PR campaign by the North Carolina company, Sprout, that involved charging the FDA with sexism and busing dozens of women to FDA hearings where they offered tearful testimony about the havoc not wanting to have sex was wreaking on their lives. According to Sprout, more than 40 percent of all women are experiencing sexual dysfunction.